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Abstract
Prostate adenocarcinoma is the most common malignancy and the second leading cause of cancer related deaths
in men. Testicular liposarcomas are uncommon soft tissue neoplasms. We report coexistence of prostate cancer
and testicular liposarcoma in a 69 year-old-man because while orchiectomy endications are decreasing day by day,
these second malignancies should not be missed.
Introduction
Prostate adenocarcinoma is the most common malig-
nancy in men and also the leading cause of cancer
related death. Sarcomas of the genitourinary tract
account for 5% of these cases and 2% of all urological
tumors. The testis is the most commonly involved uro-
logical site and accounts for approximately 30% of all
genitourinary sarcomas [1].
Testicular liposarcomas are uncommon soft tissue
neoplasms. Liposarcomas, account for 20-50% of sarco-
mas, seen in the paratesticular region [2,3]. Preoperative
diagnosis is infrequent, these tumours sometimes pre-
sent in elderly adults with a palpable mass of the ingu-
inal canal or scrotum. These tumours may arise from
the spermatic cord, fatty tissue or malignant transforma-
tion of a pre-existing lipoma [4]. Three pathologic cate-
gories of liposarcoma are recognized; well differentiated,
myxoid/round cell and pleomorphic. Most paratesticular
liposarcomas are well differentiated [5,6]. They fre-
quently have a good prognosis because of their low
grade of malignancy [7].
The relative rarity of adult testicular sarcomas has
meant that the information used to guide treatment is
based on previous experiences from various groups of
few patients. Treatment options have invariably been
evaluated in previous studies [8,9]. It has a high rate of
survival over 5 years [10].
Case presentation
In 2005; during a 69-year-old Asian origin Turkish
man’s routine controls, elevated prostate spesific antigen
(PSA) levels was determined. His prostate biopsy
appointed as adenocarcinoma with a score of Gleason 2
+3 (Figure 1). He has type II diabetes mellitus and
hypertension. There was no attribute in his family story
and systemic investigation. An abdominal CT scan eval-
uated prostate’s dimensions as 47 × 37 × 33 mm and no
additional pathological evidance was determined. In
bone scan imaging, increased uptake of right tenth rib
and left seventh rib were interpreted as malignancy. It
was accepted as stage IV prostate carcinoma and radical
orchiectomy was applied. In its microscopic investiga-
tion where left testis was normal, low grade liposarcoma
was appointed in right testis (Figure 2).
In computed tomography scan of chest, no positive
finding was determined. Radiation theraphy with 70 Gy
was employed to prostate between July-September 2006.
Because of obtaining synchroneous liposarcoma, adju-
vant systemic therapy was given as four cure of IMA
(Adriamycin (60 mg/m
2)1
st, İfosfamide (2.5 g/m
2)1
st,
2
nd,3
rd,M e s n a( 2 . 5g / m
2)1
st,2
nd,3
rd days of every 21
day) in October-December 2006. In September 2008, his
PSA and fPSA levels were <0.002 and no differentiation
was determined in bone scan imaging.
Discussion
In recent years, hormone therapy (ADT) has been more
choosen than surgical treatment for hormonal depriva-
tion. Like our case; the second and important malignen-
cies could be missed. While orchiectomy endications are
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not be missed. Our purposes in this case are to show
the coexistence of prostate cancer and rare testicular
neoplasm ‘liposarcoma’ and evaluate the treatment with
literature.
The current guidelines recommends castration alone
with either an orchiectomy or LHRH agonists. Patients
with widely advanced and metastatic prostate cancer
were previously treated with bilateral orchiectomy.
Since the introduction of LHRH agonist therapy, surgi-
cal intervention has been practiced less often [11]. In
our case if medical hormonal therapy was chosen, the
diagnose of liposarcoma would be determined later.
A recent meta-analysis included 22 trials with 5710
advanced prostate cancer patients, applied both medi-
cal castration and bilateral orchiectomy or one of them
alone. Statistically no significant survival advantage was
found with combined androgen blockage [12].
Although ADT is associated with high responses, its
curative potential is limited and unfortunately nearly
all patients develop resistance to hormonal therapy. In
a study, 938 locally advanced or asymptomatic meta-
static prostate cancer patients received treatment with
orchiectomy or LHRH agonist either immediately or
after symptoms occurred. Development of disease
releated event was twice as common in the deferred-
treatment group [13].
Testicular liposarcomas are uncommon cases in the
literature. Its coexistence with another malignancy is
rare. Although prostate cancer patients have higher
risk of a second cancer than general population. The
most frequently observed second malignancies in pros-
tate cancer patients include carcinomas of the bladder,
stomach, colon and lesser cutaneous and hematolym-
phoid malignancies The cause of death was always
from the second neoplasia [14-16]. In 312 prostate
cancer patients, 60 multiple malignant neoplasms
(MMNs) was diagnosed. In 13 of them, prostate cancer
and other malignancies were diagnosed simultaneously
[17]. Another study with 392 patients who were trea-
ted for urologic cancers, 42 cases diagnosed with
MMNs and only 16 patients (35%) had synchronous
MMNs. The incidence of prostatic cancer was higher
than other single MMNs associated with genitourinary
o r g a n s .I nt h i ss t u d y ,t h ei n c i d e n c eo fM M N sw i t h
genitourinary cancer was as high as 10.6% and the
prognosis of these patients was poor [18]. In 397
patients with urinary system tumors, second malig-
nancy were determined in 29 patients (6.6%) and 21 of
them had urological malignancy with the incidence of
6.1%. Another current study follows up with 983
patients who were diagnosed as prostate cancer and
whom 106 (11.5%) developed a MMN for sixteen
years. Uriary bladder cancer and malignant lymphoma
occured in these patients [19].
In our case because liposarcoma was determined
after radical orchiectomy, we decided the treatment
choice as radiotherapy and four cycles of IMA as a
chemotherapy regiment. The optimum local and sys-
temic treatment for these tumours remains controver-
sial, but there is a general consensus that all testicular
sarcomas in adults should be managed with radical
orchiectomy. Adjuvant locoregional radiation and/or
chemotherapy apparently diminishes the risk of local
relaps [8,9,20].
Consent
Written informed consent was obtained from the patient
for publication of this case report and any images. A
copy of the written consent is available for review by
the editor-in-Chief of this journal.
Figure 1 Acinar type prostate adenocarcinoma, Gleason score
2+3.
Figure 2 Atypic lypoblasts, propelled to edge nucleusus with
vesicular and notched cytoplasm (HE ×40).
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